Medical Treatment of "High-Risk" Neurofibromas

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Spectrum Health Hospitals.
Recruitment status was  Recruiting
Information provided by:
Spectrum Health Hospitals Identifier:
First received: January 16, 2009
Last updated: September 22, 2009
Last verified: September 2009

January 16, 2009
September 22, 2009
October 2008
October 2010   (final data collection date for primary outcome measure)
Tumor response based on evaluation of symptom assessment, tumor measurements, and MRI studies - Toxicity of treatment combinations based upon laboratory studies and physical examination [ Time Frame: Monthly physical exam first three months and then every three months after, MRI's will occur at baseline, 6, 12 and 24 months. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00846430 on Archive Site
Psychological toxicity based upon psychological evaluations - Improved quality of life based upon physical examination and performance scales [ Time Frame: Psychological evaluation at baseline, 3, 12, and 24 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Medical Treatment of "High-Risk" Neurofibromas
Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies

Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.

The study's design involves treating eligible patients with a combination of celecoxib and pegylated interferon alpha-2b. If the patients have at least a partial response after six months, they may continue on the same treatment for up to two years. If the patient experiences less than a partial response, or has progressive disease after six months of therapy, then vincristine and temozolomide will be added to the celecoxib and interferon alpha-2b backbone. Response to treatment will be assessed after a minimum of six months, presuming the patient has not experienced progressive disease. Total duration of therapy on study is two years for any individual treatment plan.

Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Neurofibromatosis 1
  • Drug: Peg-Interferon alpha-2b
    age and weight dependant
  • Drug: Celecoxib (Celebrex)
    age and weight dependant
  • Drug: Temozolomide (temodar)
    age and weight dependant
  • Drug: Vincristine Sulfate (Oncovin)
    age and weight dependant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • "High-Risk" Plexiform Neurofibromas associated with a diagnosis of NF1
  • 2-30 years old (minimum bodyweight of 10 kilograms)
  • Adequate renal function

Exclusion Criteria:

  • Previously untreated active optic glioma
  • History of any previous allergy to study medications
  • History of ischemic vascular disease
  • Pregnancy / Breast feeding
2 Years to 30 Years
Contact: Sara Finton, RN 616-391-9365
Contact: Heidi Smith, RN 616-391-9364
United States
2008-260, 2008-260
Albert Cornelius, Helen DeVos Childrens Hospital
Spectrum Health Hospitals
Not Provided
Principal Investigator: Albert S Cornelius, MD Helen DeVos Children's Hospital
Spectrum Health Hospitals
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP